Abstract
Some basic issues relevant for demonstration of superior efficacy are discussed with the case of the development of zoledronic acid 4 and 8 mg in hypercalcemia of malignancy. Topics such as number of studies, significance level, consistency of results across subgroups, and choice of primary efficacy variable are addressed. Two calibration studies using a comparison with a prespecified value as a criterion for efficacy are compared with one between-treatment pooled analysis. A further point is the switch from noninferiority to superiority. Some lessons for statistics can be drawn from the case study.
Similar content being viewed by others
References
Warrell RP. Metabolic emergencies. In: DeVita V. Jr, Hellman S, Rosenberg SA, ed. Cancer: Principles and Practice of Oncology. Ed. 5. Philadelphia, PA: Lippincott-Raven; 1997:2486–2493.
Mundy GR. Hypercalcemia of malignancy. Am J Med 1997;103:134–145.
Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–567.
Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557–1561.
Fisher LD. One large, well-designed, multicenter study as an alternative to the usual FDA paradigm. Drug Inf J 1999;33:265–271.
Ruberg S, Cairns V. Providing evidence of efficacy for a new drug. Stat Med 1998;17:1813–1823.
Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/2330/99 Draft. Points to consider on validity and interpretation of meta-analyses, and one pivotal trial. Brussels, Belgium: Committee for Proprietary Medicinal Products; October 19, 2000.
US Department of Health and Human Services, FDA CDE. and CBER. Guidance for industry: Providing clinical evidence of effectiveness for human drug and biological products. Rockville, MD: Food and Drug Administration; May 1998.
Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/482/99 Final. Points to consider on switching between superiority and non-inferiority. Brussels, Belgium: Committee for Proprietary Medicinal Products; July 27, 2000.
Bauer P, Kieser M. A unifying approach for confidence intervals and testing of equivalence and difference. Biometrika 1996;83:934–937.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quebe-Fehling, E. A Case Study Demonstrating Superiority of a New Compound over the Gold Standard. Ther Innov Regul Sci 35, 1173–1178 (2001). https://doi.org/10.1177/009286150103500414
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150103500414